Skip to content
value.today

Equilibre BioPharmaceuticals Corp.

🇺🇸 New York, New York, USAPharmaceuticalsFounded 2020
Total raised
$48 M
3 rounds on record
Latest round
$6 M
Nov 2022
First round on record
Nov 2020
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Equilibre BioPharmaceuticals Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2022$6 MNo. 3$2 to $10 million

Equilibre BioPharmaceuticals Corp.: Raise no. 3, Nov 2022

Investors in this round

13 investors had bought by the notice of Dec 1, 2022: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Philip A. Barach · Executive Officer, Director
  • Steven N. Gordon · Executive Officer, Director
  • Christina A. Ramirez · Director
  • Christopher M. Thorn · Director
  • David A. Friedman · Director
  • Francois A. Maisonrouge · Director
  • Peter M. Simon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Steven N. Gordon, Chief Operating Officer. Source: SEC Form D and 1 amendment, newest notice filed Dec 1, 2022. Read the notice at the SEC.

equitySEC
Jan 2022$16 MNo. 2$10 to $50 million

Equilibre BioPharmaceuticals Corp.: Raise no. 2, Jan 2022

Investors in this round

14 investors had bought by the notice of Jan 20, 2022: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$16 M of $25 M offered; $9 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Samuel Waksal · Executive Officer, Director
  • Steven Gordon · Executive Officer, Director
  • David Friedman · Director
  • Francois Maisonrouge · Director
  • Joel Marcus · Director
  • Peter Simon · Director
  • Philip Barach · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Steven Gordon, Chief Operating Officer and Secretary. Source: SEC Form D, newest notice filed Jan 20, 2022. Read the notice at the SEC.

equitySEC
Nov 2020$26 MNo. 1$10 to $50 million

Equilibre BioPharmaceuticals Corp.: Raise no. 1, Nov 2020

Investors in this round

14 investors had bought by the notice of Nov 12, 2020: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$26 M of $36 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Sam Waksal · Executive Officer
  • Steven Gordon · Executive Officer
  • David Friedman · Director
  • Francois Maisonrouge · Director
  • Joel Marcus · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Steven Gordon, Secretary. Source: SEC Form D, newest notice filed Nov 12, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Equilibre BioPharmaceuticals Corp. chose not to state its revenue in its newest notice of a funding round (Dec 2022).

    SEC Form D · Dec 2022

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Dec 2022

That is all the official record says: Equilibre BioPharmaceuticals Corp. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Equilibre BioPharmaceuticals Corp. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 14 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Equilibre BioPharmaceuticals Corp.
NameRoleNamed in
Christopher M. ThornExecutive officerDec 2022
Philip A. BarachExecutive officerDec 2022
Steven N. GordonExecutive officerDec 2022
Samuel WaksalExecutive officerJan 2022
Steven GordonExecutive officerJan 2022
Sam WaksalExecutive officerNov 2020
Christina A. RamirezDirectorDec 2022
Christopher M. ThornDirectorDec 2022
David A. FriedmanDirectorDec 2022
Francois A. MaisonrougeDirectorDec 2022
Peter M. SimonDirectorDec 2022
Philip A. BarachDirectorDec 2022
Steven N. GordonDirectorDec 2022
David FriedmanDirectorJan 2022
Francois MaisonrougeDirectorJan 2022
Joel MarcusDirectorJan 2022
Peter SimonDirectorJan 2022
Philip BarachDirectorJan 2022
Samuel WaksalDirectorJan 2022
Steven GordonDirectorJan 2022